Novartis Q1 Profit Tumbles 18% on Generic Competition, Manufacturing Problems (NVS)

Drug maker Novartis AG (NVS) on Tuesday said its first quarter earnings fell 18% from last year, hurt by competition from new generic drugs as well as production problems in the U.S.

The Swiss company reported first quarter net income of $2.33 billion, down from $2.82 billion in the year-ago period. Net sales fell 2% from last year to $13.74 billion.

Those results were largely in-line with what analysts had predicted.

On a sour note, Novartis said it expects full-year 2012 earnings to come in below 2011 levels.

Novartis shares fell 85 cents, or -1.5%, in morning trading Tuesday.

The Bottom Line
We recently began recommending shares of Novartis (NVS) since Mar.21, when the stock price was at $55.46. The company has a 4.42% dividend yield, based on last night’s closing stock price of $55.62.

Novartis AG (NVS) is a “Recommended” dividend stock, holding a DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here